{"ticker": {"uuid": "cd5daa06-74f9-4b4b-a6a7-1e66f4769806", "symbol": "RANI", "name": "Rani Therapeutics Holdings Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Rani Therapeutics Tries To Turn Biologic Shots Into Pills", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ERkw4VklnbFNxdXliTU1QOEh1SVIyeWItWlBaOXRkMnlJUGMwSWlpUkNxVF9pWXZUaEVvdVo0X3A2YjR0ZGJIQm5RRXQ1VmthR29mSEZOTDRIRUhQ?oc=5", "source_name": "Finimize", "published_at": "2026-07-15T21:27:56+00:00", "published_display": "15 Jul 2026 21:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics reports positive Phase 1 data for oral obesity drug", "summary": "Rani Therapeutics announced positive initial data from its Phase 1 study of RT-114, an oral capsule for obesity treatment, showing systemic exposure greater than 150% relative to subcutaneous injection with mild, transient side effects. The company plans to expand the Phase 1a st", "url": "https://m.uk.investing.com/news/stock-market-news/rani-therapeutics-reports-positive-phase-1-data-for-oral-obesity-drug-93CH-4771706?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T16:10:08", "published_display": "15 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Reports Positive Phase 1a Data for Oral RT-114, Achieving Greater Than 150% Systemic Exposure Versus Matched Subcutaneous Dose", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxOTEtiWDlfWjZNUmpPaU4tQ3g1Sk5tREVDUmlMQk5Xamg2LXZNUDB1ODZqTXlkZnBOdmJxWlJLUGJtRFIxaWxFMEVvNFJMdlBuY1hUOWZBQWRvakU4Z1hjY3pXQ0k4SEhaSEZicWpHdEpTTnFlUGs5RGFJa3U4c1JIbUJmaU15Ri1fT0sycHZwOGJlZVNWMHIxdWtlLWNJQ2p0SkpIWmlqb0ZQOU1DNlhidEdUck9LWmRtUnQ4aXJQNzFETzJJWU1NYWNGdFlXTy1zYlpjeUhkMjE3dFYwMmdIUWxRYV8zeF9scnd3czZGTFdua1FxLW9KQ3FSWDMyNXd0UnNIekxVRDFBTzRnckE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T12:13:00+00:00", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-announces-positive-initial-120000108.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani\u2019s oral obesity treatment shows 150%+ exposure vs. injection", "summary": "Rani Therapeutics reported positive initial Phase 1a data for its oral obesity treatment, RT-114, which demonstrated bioavailability exceeding 150% compared to a matched subcutaneous injection of PG-102. The study in 30 healthy volunteers showed no serious adverse events, with mi", "url": "https://www.stocktitan.net/news/RANI/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-cnyhyzssslpf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:10:08", "published_display": "15 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rani Therapeutics (RANI) CFO Nicholas Maestas files initial Form 3 ownership", "summary": "Rani Therapeutics Holdings, Inc. CFO Nicholas Maestas filed his initial Form 3, an ownership report, on July 8, 2026. This filing serves as a baseline disclosure of his status as a reporting officer", "url": "https://www.stocktitan.net/sec-filings/RANI/form-3-rani-therapeutics-holdings-inc-initial-statement-of-beneficial-bd1ad9bf9011.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:11:57", "published_display": "09 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-announces-research-development-200500900.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Rani Therapeutics (NASDAQ: RANI) CFO granted options, 2026 inducement plan", "summary": "Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) has appointed Nicholas M. Maestas as its new Chief Financial Officer, effective June 29, 2026. Maestas will receive a $500,000 annual base salary, a target bonus of 75% of his base salary, and a non-qualified option to purchase 2,00", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-c5e328595251.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:40:47", "published_display": "30 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer", "summary": "Rani Therapeutics Holdings, Inc. has announced the appointment of Nicholas Maestas as their new Chief Financial Officer, effective immediately. Maestas brings over 10 years of financial leadership experience in clinical-stage biotechnology, having previously held roles at Tempest", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-appoints-nicholas-maestas-120000540.html", "source_name": "Market source", "published_at": "2026-06-29T18:39:39", "published_display": "29 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Names Nicholas Maestas CFO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-names-nicholas-maestas-125504442.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:55:04+00:00", "published_display": "29 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings, Inc. Class A Actuals & Estimates (NASDAQ:RANI)", "summary": "This article provides an overview of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, earnings estimates, and revenue figures, noting the company's next earning", "url": "https://www.tradingview.com/symbols/NASDAQ-RANI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:34", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RANI SEC Filings - Rani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Rani Therapeutics Holdings, Inc. (RANI) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details the company's regulatory record as a clinical-stage biotherapeutics firm developing oral", "url": "https://www.stocktitan.net/sec-filings/RANI/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T08:40:02", "published_display": "16 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity", "summary": "Rani Therapeutics Holdings, Inc. reported an insider trading activity where Chief Executive Officer Imran Talat received a grant of stock options covering 3,800,000 shares of Class A Common Stock. These options have an exercise price of $0.875 per share and vest over four years, ", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-ca72c834c841.html", "source_name": "Stock Titan", "published_at": "2026-06-05T22:39:15", "published_display": "05 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) grants CBO 805,500 stock options", "summary": "Rani Therapeutics Holdings, Inc. (RANI) reported that Chief Business Officer Kate McKinley was granted 805,500 stock options for Class A Common Stock. These options have an exercise price of $0.875 per share and expire on June 2, 2036. The shares will vest monthly over four years", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-73dc0c7d594c.html", "source_name": "Stock Titan", "published_at": "2026-06-05T22:39:15", "published_display": "05 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (NASDAQ: RANI) CTO awarded 805,500 stock options", "summary": "Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) reported that its Chief Technical Officer, Alireza Javadi, was granted 805,500 stock options. These options have an exercise price of $0.875 per share and will vest monthly over four years, starting April 1, 2026, contingent on cont", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-0b5ef815e2b0.html", "source_name": "Stock Titan", "published_at": "2026-06-05T22:39:15", "published_display": "05 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options", "summary": "Imran Mir A, a director and ten percent owner of Rani Therapeutics (NASDAQ: RANI), was granted 123,600 stock options. These options have an exercise price of $0.9515 per share and are set to expire on May 27, 2036. The stock options will vest in full on the first anniversary of t", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-f54518a4fc3d.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:31", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (NASDAQ: RANI) director receives stock options on 123,600 shares", "summary": "Rani Therapeutics Holdings director Lisa Ann Rometty was granted stock options for 123,600 Class A common stock shares. These options have an exercise price of $0.9515 per share and expire on May 27, 2036. The options will fully vest on May 28, 2027, one year from the grant date,", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-3a299f5b60b1.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:31", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Abraham Bassan receives 123,600 Rani (RANI) stock options", "summary": "Rani Therapeutics Holdings director Abraham Bassan was granted 123,600 stock options for Class A Common Stock with an exercise price of $0.9515 per share. These options represent his entire reported derivative holdings and will vest in full on the first anniversary of the grant d", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-39229249ab22.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:31", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) director granted 123,600 options at $0.9515 exercise price", "summary": "Rani Therapeutics director Bailey Vasudev Jaiprakash was granted 123,600 stock options at an exercise price of $0.9515 per share on May 28, 2026. These options vest fully on the first anniversary of the grant date, subject to continuous service, or earlier upon the next annual st", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-11d5ce9a7b2f.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:31", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Rani Therapeutics (RANI) receives 123,600 stock options as compensation award", "summary": "Rani Therapeutics Holdings director Jean Luc Butel was granted 123,600 stock options as a compensation award, not through open market purchase, with an exercise price of $0.9515 per share and an expiration date of May 27, 2036. The options vest in full on the first anniversary of", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-5bb825614362.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:31", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) director receives 123,600 stock options at $0.9515 strike", "summary": "Rani Therapeutics Holdings director Dennis A. Ausiello was granted 123,600 stock options for Class A common stock, with an exercise price of $0.9515 per share, expiring on May 27, 2036. This compensation-related award vests fully on the first anniversary of the grant date, or ear", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-959239be16c4.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:31", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Announces $20 Million Equity Financing", "summary": "Rani Therapeutics Holdings has announced a $20 million equity financing through the sale of Class A common stock and pre-funded warrants to institutional investors. The offering, expected to close around May 27, 2026, aims to provide funding flexibility for the biopharmaceutical ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RANI-Q/pressreleases/2171529/rani-therapeutics-announces-20-million-equity-financing/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T00:39:23", "published_display": "31 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RANI - Rani Therapeutics Holdings Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial data for Rani Therapeutics Holdings Inc (RANI), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and corporate events. It highlights the company's executive te", "url": "https://finviz.com/stock?t=RANI", "source_name": "Finviz", "published_at": "2026-05-29T16:13:20", "published_display": "29 May 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) stockholders elect directors and ratify 2026 auditor", "summary": "Rani Therapeutics Holdings, Inc. (RANI) held its annual stockholder meeting on May 28, 2026. Stockholders elected all seven nominated directors, including Talat Imran and Mir Imran, to serve until the 2027 annual meeting. They also ratified the appointment of CBIZ CPAs P.C. as th", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-2d8a68beab84.html", "source_name": "Stock Titan", "published_at": "2026-05-29T03:08:54", "published_display": "29 May 2026 03:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akkaraju funds lift Rani Therapeutics (RANI) beneficial stake to 9.99%", "summary": "Samsara BioCapital funds and Dr. Srinivas Akkaraju have increased their beneficial ownership in Rani Therapeutics Holdings (RANI) to 9.99% following a registered direct offering in May 2026. Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. jointly purchased 1,869,159 s", "url": "https://www.stocktitan.net/sec-filings/RANI/schedule-13d-a-rani-therapeutics-holdings-inc-amended-major-sharehold-2d2cd9311213.html", "source_name": "Stock Titan", "published_at": "2026-05-28T21:39:07", "published_display": "28 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) raises ~$19.99M via Class A shares and pre-funded warrants", "summary": "Rani Therapeutics is conducting a registered direct offering to raise approximately $19.99 million in gross proceeds by offering 12.48 million shares of Class A common stock and pre-funded warrants to purchase 6.21 million shares at $1.07 per share. The estimated net proceeds of ", "url": "https://www.stocktitan.net/sec-filings/RANI/424b5-rani-therapeutics-holdings-inc-prospectus-supplement-debt-secur-b917031264cb.html", "source_name": "Stock Titan", "published_at": "2026-05-27T10:40:36", "published_display": "27 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings, Inc. Announces Securities Purchase Agreement and Pre-Funded Warrant Offering \u2013 SEC 8-K Filing Details", "summary": "Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) has announced a significant equity financing event, entering into a Securities Purchase Agreement on May 26, 2026, with institutional investors for the issuance of common shares and pre-funded warrants. This registered offering is i", "url": "https://www.minichart.com.sg/2026/05/27/rani-therapeutics-holdings-inc-announces-securities-purchase-agreement-and-pre-funded-warrant-offering-sec-8-k-filing-details/", "source_name": "Minichart", "published_at": "2026-05-27T10:40:36", "published_display": "27 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics to Raise ~$20M via $1.07 Share Offering and Pre-Funded Warrants", "summary": "Rani Therapeutics has entered into a securities purchase agreement to raise approximately $20.0 million through an offering of Class A shares and pre-funded warrants. The offering involves 12,476,637 Class A shares and pre-funded warrants for 6,214,953 shares, with pricing set at", "url": "https://www.tradingview.com/news/tradingview:a4d8ee73a5a18:0-rani-therapeutics-to-raise-20m-via-1-07-share-offering-and-pre-funded-warrants/", "source_name": "TradingView", "published_at": "2026-05-27T10:40:36", "published_display": "27 May 2026 10:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) prices $20M stock and pre-funded warrant sale", "summary": "Rani Therapeutics has priced a registered offering to raise approximately $20.0 million in gross proceeds through the sale of Class A common stock and pre-funded warrants. The offering includes over 12.4 million shares at $1.07 each and more than 6.2 million pre-funded warrants a", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-9709ed3ebbaf.html", "source_name": "Stock Titan", "published_at": "2026-05-27T09:40:36", "published_display": "27 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics raises $20 million in direct offering", "summary": "Rani Therapeutics Holdings Inc. announced a registered direct offering to raise approximately $20 million, selling Class A common stock and pre-funded warrants. The offering, led by a sovereign wealth fund, aims to boost the clinical-stage biotherapeutics company's capital despit", "url": "https://m.uk.investing.com/news/stock-market-news/rani-therapeutics-raises-20-million-in-direct-offering-93CH-4698237?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-26T18:40:36", "published_display": "26 May 2026 18:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules", "summary": "Rani Therapeutics Holdings, Inc. announced a registered direct offering of Class A common stock and pre-funded warrants, expecting to raise approximately $20.0 million. The offering, priced at-the-market under Nasdaq rules, involves a sovereign wealth fund and other healthcare-fo", "url": "https://www.globenewswire.com/news-release/2026/05/26/3301000/0/en/rani-therapeutics-holdings-inc-announces-pricing-of-20-0-million-registered-direct-offering-of-class-a-common-stock-priced-at-the-market-under-nasdaq-rules.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:38:55", "published_display": "26 May 2026 11:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sovereign wealth fund leads $20M raise for oral drug delivery firm", "summary": "Rani Therapeutics announced a registered direct offering of Class A common stock and pre-funded warrants, expecting to raise approximately $20.0 million in gross proceeds. The financing, led by a sovereign wealth fund, involves the issuance of 12,476,637 shares and 6,214,953 pre-", "url": "https://www.stocktitan.net/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-20-0-million-ww1tzj55ooqc.html", "source_name": "Stock Titan", "published_at": "2026-05-26T11:38:55", "published_display": "26 May 2026 11:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates Buy on Rani Therapeutics stock, $5 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVTE0N1BIdW1OTG9qRkMyclFpZF9zdmZsUGdQZVBpM1paYTBEa1FkbGVIUVE0VHB4VTNQUmJIamdWRmg2NXZRZ2lzRV8wcVdEVlFJc3F0eGpHa0REZmY0N0JSdlhudHhBeDJzNm5sLWlMSW5pUnBkMDZNd1ZEazNERG44clBVNlBtcGpBVi1PTkw1NGFQTDROTTkxZy1HV3dBVnZPcE81dG9nMUNyOWoyMnpaaDEwOXVPWDk0MQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price", "summary": "Rani Therapeutics Holdings, Inc. Class A (RANI) is facing a Nasdaq delisting risk after receiving a deficiency notice for failing to maintain a $1.00 minimum bid price for 30 consecutive trading days. The company's Class A common stock could be delisted, which would severely impa", "url": "https://www.tipranks.com/news/company-announcements/nasdaq-delisting-risk-looms-as-rani-therapeutics-fails-to-meet-1-minimum-bid-price", "source_name": "TipRanks", "published_at": "2026-05-17T05:40:14", "published_display": "17 May 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition", "summary": "Rani Therapeutics reported improved Q1 2026 financial results with increased contract revenue and a narrowed net loss, and expects its cash reserves to fund operations into Q4 2027. However, the company received a Nasdaq warning for failing to meet the minimum bid price requireme", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-dccfb26aea67.html", "source_name": "Stock Titan", "published_at": "2026-05-16T11:42:12", "published_display": "16 May 2026 11:42", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQU2Z5ZGotVVVTbmJwV0t3NXlTZHh5cjNzejJ5U3JUcEtvemZNZE1fX0xTVnJISzREbzZOZ2pPTVdfSWhNWUxzTDc0Y3ROUGJTTW5pcFN6eG0weEF4R0RmRmNLaTY2X2tXaDFOZU1hU21WMmxmN2RuRDFtTEhielB3akdGQXhlMTZweGppSmp0UXRpSExLNl9pb2lHY3FTUXJFV0VNLVVJZlRlRHJP?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/news/rani-therapeutics-participate-h-c-200500021.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rani-therapeutics-holdings-insider-increased-111101166.html", "source_name": "Simply Wall St.", "published_at": "2026-05-08T11:11:01+00:00", "published_display": "08 May 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPXzYxNG5tbVQ3Uno4WkF3aG8xTkxwZzBRUmZwdUl1TU1qYzZ4SkF4NGFUTzVGRTY3Qi1VOEJsaHFDY1N2WWJPNURjWXc1ejZjZkZWVzF4dld0LU1ZVHBtUlFFd216MU0tVndtZE95THVBdmZpamRlb3plNXhpMVVnUTNkcHh6WC1sSUZ5aHJGMlBOaDVJcVZPTC1YUXZWVkZtNDFlSUo3WG1uUnNP?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNbWE3dVAtdE5PU1FXVUk3M3pTY1JySGs5YTdUd1NPSWdjcFFPN21pQkVoYmJ1YXl1aXBaN2oxU1VUWk1RS2Voc01fNUdDUVZ2dVRpalJOblFYbVFxSk5SSlRfZHNKbzc5Mm1UN1pDQ3dmU1FSeERzY0VCalN0RFlrU2lLX2ltWktzRVl0WnhsdDRPVWg3dmVzRHdVdEtEN2o0UVBFcnBaNkhpTl9DU2c?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI): Valuation in Focus After Landmark Chugai Deal and Breakthrough Clinical Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Rani Therapeutics (RANI) Is Up 23.6% After Promising Oral Semaglutide Preclinical Data Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8gFBVV95cUxQVC1yMjRJcjRUbU94OV9SOC1YLVhDOFFObzNvd3ZpdDcxZGxQQl9Gak5tY3BaZWt3YVlaSmhsamlMMHBwNnExZHl3cHVmV2FMbnE1LUdJc1VSUmxpOEpYc3J3VUozY1Ryd090a0Roc1o0cGJTX21vSTVnTFZiUHhtVnE1SmxwYVZNWWFsaGM2dnVLVVQ2Z0FnN0k0WnRjajd2VU9ONnFvUWFRQ1VtQS1ST3o2Mzl3TENUT201dWVKVFZrZ1FEZmtuWElocmRNOUxjZXR6cUt1WkM5b056NC1iSXZESDdhUktOV0x5ZVdiZm9LUdIB9wFBVV95cUxPV2pKa0pSQXNPQlI1aG5MOFFJNjZqSGN2SzdTVGVQS1cwSnVPV2dnVkE0SVY0UFNQNVZSM1pvUEFFS1NpZFNxNS1DWTdVNjBkRGhmVkN5ZllIcmx2cWRIc0pWTzJmZ3kyNVBrV0Q0eWUxbXFWaHNHRnBUT09zN2lrQUtDa2E0UVVJMDJjdnV5N0E1LUNfRDBSczg5eUszdVJIQnZtTUNnVTlkTklRQmxlaHVDMHRGY25HZ0djdzlwQlF0V0RmT0xCNWI1eUwzenRjcVd5bzZwV1MwSGNXYmNEaFIyaHZ0Z1pPWjdXSHJmZ2pNcEhYVDRj?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending tickers: latest investor updates on Apple, Beyond Meat, Rani Therapeutics, BitMine and B&M", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQy1lalVZc3prZ0l1LWJBTUt5aW9BNW5UOGJ1TmdzcFVkSjFWemRMSG9sNlNpQlktNHBGajJvSXNaZXNqUjlsV0xBZmlWcUxJSVh0R2lpa1pDUnpfTk9CTTNOcE84MWRwdm5GRWl5RkxvbmdBaG8xN1I5bjJDdlZsMl9hUHVQUzdOVlhEOWg0ZG1QeENLZjZCeDE3Z3N3a05LY1E4SGdNWjI3TXdLVGt2cGZR?oc=5", "source_name": "Market source", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Rani Therapeutics\u2019 Stock Skyrocketing Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRGdFdFJDSzRrY1hnN2FqZFFxNHZpYlU0TWpvUmxkSm9MUVM1WndKX2FKVlczakkydGNqYUota09jNEwwb3ZKV1ZkMFZrNmtkZFQ5ZXFQelpGNTFZYWh6Mmpoa2FpV1VWSFZaMEJpYmF1NTR3Q2Q4NW95eUZmdGUzOG1sblB3UFEwc2VObUlKU3lwMjFQOWkyejJ5WU1hV0tCX05TM2Fqck5HVXZMUm9KZFk2aVNsemlWNVFXMWJTcElKZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-17T07:00:00+00:00", "published_display": "17 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings (RANI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9jMWY4aW5GTnlGSHgxWVRYbkhoRk51a2xBd2VvZTIyX2xLM0xUTTVUMzNnLTM4NnR4cVp3MkMtQTNxc0lCUHU1SzJreFpQVTA5QXlB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:24:30+00:00", "published_display": "25 Apr 2025 01:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Stock: Excellent Technology But Major Risks Ahead (NASDAQ:RANI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOYXpPV25xa3drX3RILWJab0lGLXRuYVZQdEFCdVFSNmNTM3dWMldiSWdoNFVQYmFSUUdVWFNWVWlpZ2FQWXd3TUV3VFFfT1ZLMllSRXlMOHRjcF9xNFNTVXNrbk9iYzd0bWVMaERaSm1aSmdnREZRNjhRSHFUUXVZT3M5SDRQVDNUR1lYbTd0MlFLZDhiNUpiYTh4V2N1Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2023-09-19T07:00:00+00:00", "published_display": "19 Sep 2023 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Rani Therapeutics Tries To Turn Biologic Shots Into Pills", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ERkw4VklnbFNxdXliTU1QOEh1SVIyeWItWlBaOXRkMnlJUGMwSWlpUkNxVF9pWXZUaEVvdVo0X3A2YjR0ZGJIQm5RRXQ1VmthR29mSEZOTDRIRUhQ?oc=5", "source_name": "Finimize", "published_at": "2026-07-15T21:27:56+00:00", "published_display": "15 Jul 2026 21:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics reports positive Phase 1 data for oral obesity drug", "summary": "Rani Therapeutics announced positive initial data from its Phase 1 study of RT-114, an oral capsule for obesity treatment, showing systemic exposure greater than 150% relative to subcutaneous injection with mild, transient side effects. The company plans to expand the Phase 1a st", "url": "https://m.uk.investing.com/news/stock-market-news/rani-therapeutics-reports-positive-phase-1-data-for-oral-obesity-drug-93CH-4771706?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-15T16:10:08", "published_display": "15 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Reports Positive Phase 1a Data for Oral RT-114, Achieving Greater Than 150% Systemic Exposure Versus Matched Subcutaneous Dose", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgJBVV95cUxOTEtiWDlfWjZNUmpPaU4tQ3g1Sk5tREVDUmlMQk5Xamg2LXZNUDB1ODZqTXlkZnBOdmJxWlJLUGJtRFIxaWxFMEVvNFJMdlBuY1hUOWZBQWRvakU4Z1hjY3pXQ0k4SEhaSEZicWpHdEpTTnFlUGs5RGFJa3U4c1JIbUJmaU15Ri1fT0sycHZwOGJlZVNWMHIxdWtlLWNJQ2p0SkpIWmlqb0ZQOU1DNlhidEdUck9LWmRtUnQ4aXJQNzFETzJJWU1NYWNGdFlXTy1zYlpjeUhkMjE3dFYwMmdIUWxRYV8zeF9scnd3czZGTFdua1FxLW9KQ3FSWDMyNXd0UnNIekxVRDFBTzRnckE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T12:13:00+00:00", "published_display": "15 Jul 2026 12:13", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-announces-positive-initial-120000108.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T12:00:00+00:00", "published_display": "15 Jul 2026 12:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani\u2019s oral obesity treatment shows 150%+ exposure vs. injection", "summary": "Rani Therapeutics reported positive initial Phase 1a data for its oral obesity treatment, RT-114, which demonstrated bioavailability exceeding 150% compared to a matched subcutaneous injection of PG-102. The study in 30 healthy volunteers showed no serious adverse events, with mi", "url": "https://www.stocktitan.net/news/RANI/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-cnyhyzssslpf.html", "source_name": "Stock Titan", "published_at": "2026-07-15T12:10:08", "published_display": "15 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) CFO Nicholas Maestas files initial Form 3 ownership", "summary": "Rani Therapeutics Holdings, Inc. CFO Nicholas Maestas filed his initial Form 3, an ownership report, on July 8, 2026. This filing serves as a baseline disclosure of his status as a reporting officer", "url": "https://www.stocktitan.net/sec-filings/RANI/form-3-rani-therapeutics-holdings-inc-initial-statement-of-beneficial-bd1ad9bf9011.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:11:57", "published_display": "09 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-announces-research-development-200500900.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T20:05:00+00:00", "published_display": "09 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Rani Therapeutics (NASDAQ: RANI) CFO granted options, 2026 inducement plan", "summary": "Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) has appointed Nicholas M. Maestas as its new Chief Financial Officer, effective June 29, 2026. Maestas will receive a $500,000 annual base salary, a target bonus of 75% of his base salary, and a non-qualified option to purchase 2,00", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-c5e328595251.html", "source_name": "Stock Titan", "published_at": "2026-06-30T09:40:47", "published_display": "30 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer", "summary": "Rani Therapeutics Holdings, Inc. has announced the appointment of Nicholas Maestas as their new Chief Financial Officer, effective immediately. Maestas brings over 10 years of financial leadership experience in clinical-stage biotechnology, having previously held roles at Tempest", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-appoints-nicholas-maestas-120000540.html", "source_name": "Market source", "published_at": "2026-06-29T18:39:39", "published_display": "29 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Names Nicholas Maestas CFO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rani-therapeutics-names-nicholas-maestas-125504442.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:55:04+00:00", "published_display": "29 Jun 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings, Inc. Class A Actuals & Estimates (NASDAQ:RANI)", "summary": "This article provides an overview of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, earnings estimates, and revenue figures, noting the company's next earning", "url": "https://www.tradingview.com/symbols/NASDAQ-RANI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:40:34", "published_display": "26 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RANI SEC Filings - Rani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive overview of Rani Therapeutics Holdings, Inc. (RANI) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details the company's regulatory record as a clinical-stage biotherapeutics firm developing oral", "url": "https://www.stocktitan.net/sec-filings/RANI/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-16T08:40:02", "published_display": "16 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity", "summary": "Rani Therapeutics Holdings, Inc. reported an insider trading activity where Chief Executive Officer Imran Talat received a grant of stock options covering 3,800,000 shares of Class A Common Stock. These options have an exercise price of $0.875 per share and vest over four years, ", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-ca72c834c841.html", "source_name": "Stock Titan", "published_at": "2026-06-05T22:39:15", "published_display": "05 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) grants CBO 805,500 stock options", "summary": "Rani Therapeutics Holdings, Inc. (RANI) reported that Chief Business Officer Kate McKinley was granted 805,500 stock options for Class A Common Stock. These options have an exercise price of $0.875 per share and expire on June 2, 2036. The shares will vest monthly over four years", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-73dc0c7d594c.html", "source_name": "Stock Titan", "published_at": "2026-06-05T22:39:15", "published_display": "05 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (NASDAQ: RANI) CTO awarded 805,500 stock options", "summary": "Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) reported that its Chief Technical Officer, Alireza Javadi, was granted 805,500 stock options. These options have an exercise price of $0.875 per share and will vest monthly over four years, starting April 1, 2026, contingent on cont", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-0b5ef815e2b0.html", "source_name": "Stock Titan", "published_at": "2026-06-05T22:39:15", "published_display": "05 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options", "summary": "Imran Mir A, a director and ten percent owner of Rani Therapeutics (NASDAQ: RANI), was granted 123,600 stock options. These options have an exercise price of $0.9515 per share and are set to expire on May 27, 2036. The stock options will vest in full on the first anniversary of t", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-f54518a4fc3d.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:31", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (NASDAQ: RANI) director receives stock options on 123,600 shares", "summary": "Rani Therapeutics Holdings director Lisa Ann Rometty was granted stock options for 123,600 Class A common stock shares. These options have an exercise price of $0.9515 per share and expire on May 27, 2036. The options will fully vest on May 28, 2027, one year from the grant date,", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-3a299f5b60b1.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:31", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Abraham Bassan receives 123,600 Rani (RANI) stock options", "summary": "Rani Therapeutics Holdings director Abraham Bassan was granted 123,600 stock options for Class A Common Stock with an exercise price of $0.9515 per share. These options represent his entire reported derivative holdings and will vest in full on the first anniversary of the grant d", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-39229249ab22.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:39:31", "published_display": "01 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) director granted 123,600 options at $0.9515 exercise price", "summary": "Rani Therapeutics director Bailey Vasudev Jaiprakash was granted 123,600 stock options at an exercise price of $0.9515 per share on May 28, 2026. These options vest fully on the first anniversary of the grant date, subject to continuous service, or earlier upon the next annual st", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-11d5ce9a7b2f.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:31", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Rani Therapeutics (RANI) receives 123,600 stock options as compensation award", "summary": "Rani Therapeutics Holdings director Jean Luc Butel was granted 123,600 stock options as a compensation award, not through open market purchase, with an exercise price of $0.9515 per share and an expiration date of May 27, 2036. The options vest in full on the first anniversary of", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-5bb825614362.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:31", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) director receives 123,600 stock options at $0.9515 strike", "summary": "Rani Therapeutics Holdings director Dennis A. Ausiello was granted 123,600 stock options for Class A common stock, with an exercise price of $0.9515 per share, expiring on May 27, 2036. This compensation-related award vests fully on the first anniversary of the grant date, or ear", "url": "https://www.stocktitan.net/sec-filings/RANI/form-4-rani-therapeutics-holdings-inc-insider-trading-activity-959239be16c4.html", "source_name": "Stock Titan", "published_at": "2026-06-01T19:39:31", "published_display": "01 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Announces $20 Million Equity Financing", "summary": "Rani Therapeutics Holdings has announced a $20 million equity financing through the sale of Class A common stock and pre-funded warrants to institutional investors. The offering, expected to close around May 27, 2026, aims to provide funding flexibility for the biopharmaceutical ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RANI-Q/pressreleases/2171529/rani-therapeutics-announces-20-million-equity-financing/", "source_name": "The Globe and Mail", "published_at": "2026-05-31T00:39:23", "published_display": "31 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RANI - Rani Therapeutics Holdings Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial data for Rani Therapeutics Holdings Inc (RANI), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and corporate events. It highlights the company's executive te", "url": "https://finviz.com/stock?t=RANI", "source_name": "Finviz", "published_at": "2026-05-29T16:13:20", "published_display": "29 May 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) stockholders elect directors and ratify 2026 auditor", "summary": "Rani Therapeutics Holdings, Inc. (RANI) held its annual stockholder meeting on May 28, 2026. Stockholders elected all seven nominated directors, including Talat Imran and Mir Imran, to serve until the 2027 annual meeting. They also ratified the appointment of CBIZ CPAs P.C. as th", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-2d8a68beab84.html", "source_name": "Stock Titan", "published_at": "2026-05-29T03:08:54", "published_display": "29 May 2026 03:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Akkaraju funds lift Rani Therapeutics (RANI) beneficial stake to 9.99%", "summary": "Samsara BioCapital funds and Dr. Srinivas Akkaraju have increased their beneficial ownership in Rani Therapeutics Holdings (RANI) to 9.99% following a registered direct offering in May 2026. Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. jointly purchased 1,869,159 s", "url": "https://www.stocktitan.net/sec-filings/RANI/schedule-13d-a-rani-therapeutics-holdings-inc-amended-major-sharehold-2d2cd9311213.html", "source_name": "Stock Titan", "published_at": "2026-05-28T21:39:07", "published_display": "28 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) raises ~$19.99M via Class A shares and pre-funded warrants", "summary": "Rani Therapeutics is conducting a registered direct offering to raise approximately $19.99 million in gross proceeds by offering 12.48 million shares of Class A common stock and pre-funded warrants to purchase 6.21 million shares at $1.07 per share. The estimated net proceeds of ", "url": "https://www.stocktitan.net/sec-filings/RANI/424b5-rani-therapeutics-holdings-inc-prospectus-supplement-debt-secur-b917031264cb.html", "source_name": "Stock Titan", "published_at": "2026-05-27T10:40:36", "published_display": "27 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings, Inc. Announces Securities Purchase Agreement and Pre-Funded Warrant Offering \u2013 SEC 8-K Filing Details", "summary": "Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) has announced a significant equity financing event, entering into a Securities Purchase Agreement on May 26, 2026, with institutional investors for the issuance of common shares and pre-funded warrants. This registered offering is i", "url": "https://www.minichart.com.sg/2026/05/27/rani-therapeutics-holdings-inc-announces-securities-purchase-agreement-and-pre-funded-warrant-offering-sec-8-k-filing-details/", "source_name": "Minichart", "published_at": "2026-05-27T10:40:36", "published_display": "27 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics to Raise ~$20M via $1.07 Share Offering and Pre-Funded Warrants", "summary": "Rani Therapeutics has entered into a securities purchase agreement to raise approximately $20.0 million through an offering of Class A shares and pre-funded warrants. The offering involves 12,476,637 Class A shares and pre-funded warrants for 6,214,953 shares, with pricing set at", "url": "https://www.tradingview.com/news/tradingview:a4d8ee73a5a18:0-rani-therapeutics-to-raise-20m-via-1-07-share-offering-and-pre-funded-warrants/", "source_name": "TradingView", "published_at": "2026-05-27T10:40:36", "published_display": "27 May 2026 10:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI) prices $20M stock and pre-funded warrant sale", "summary": "Rani Therapeutics has priced a registered offering to raise approximately $20.0 million in gross proceeds through the sale of Class A common stock and pre-funded warrants. The offering includes over 12.4 million shares at $1.07 each and more than 6.2 million pre-funded warrants a", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-9709ed3ebbaf.html", "source_name": "Stock Titan", "published_at": "2026-05-27T09:40:36", "published_display": "27 May 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics raises $20 million in direct offering", "summary": "Rani Therapeutics Holdings Inc. announced a registered direct offering to raise approximately $20 million, selling Class A common stock and pre-funded warrants. The offering, led by a sovereign wealth fund, aims to boost the clinical-stage biotherapeutics company's capital despit", "url": "https://m.uk.investing.com/news/stock-market-news/rani-therapeutics-raises-20-million-in-direct-offering-93CH-4698237?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-26T18:40:36", "published_display": "26 May 2026 18:40", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules", "summary": "Rani Therapeutics Holdings, Inc. announced a registered direct offering of Class A common stock and pre-funded warrants, expecting to raise approximately $20.0 million. The offering, priced at-the-market under Nasdaq rules, involves a sovereign wealth fund and other healthcare-fo", "url": "https://www.globenewswire.com/news-release/2026/05/26/3301000/0/en/rani-therapeutics-holdings-inc-announces-pricing-of-20-0-million-registered-direct-offering-of-class-a-common-stock-priced-at-the-market-under-nasdaq-rules.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:38:55", "published_display": "26 May 2026 11:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sovereign wealth fund leads $20M raise for oral drug delivery firm", "summary": "Rani Therapeutics announced a registered direct offering of Class A common stock and pre-funded warrants, expecting to raise approximately $20.0 million in gross proceeds. The financing, led by a sovereign wealth fund, involves the issuance of 12,476,637 shares and 6,214,953 pre-", "url": "https://www.stocktitan.net/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-20-0-million-ww1tzj55ooqc.html", "source_name": "Stock Titan", "published_at": "2026-05-26T11:38:55", "published_display": "26 May 2026 11:38", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord reiterates Buy on Rani Therapeutics stock, $5 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPVTE0N1BIdW1OTG9qRkMyclFpZF9zdmZsUGdQZVBpM1paYTBEa1FkbGVIUVE0VHB4VTNQUmJIamdWRmg2NXZRZ2lzRV8wcVdEVlFJc3F0eGpHa0REZmY0N0JSdlhudHhBeDJzNm5sLWlMSW5pUnBkMDZNd1ZEazNERG44clBVNlBtcGpBVi1PTkw1NGFQTDROTTkxZy1HV3dBVnZPcE81dG9nMUNyOWoyMnpaaDEwOXVPWDk0MQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price", "summary": "Rani Therapeutics Holdings, Inc. Class A (RANI) is facing a Nasdaq delisting risk after receiving a deficiency notice for failing to maintain a $1.00 minimum bid price for 30 consecutive trading days. The company's Class A common stock could be delisted, which would severely impa", "url": "https://www.tipranks.com/news/company-announcements/nasdaq-delisting-risk-looms-as-rani-therapeutics-fails-to-meet-1-minimum-bid-price", "source_name": "TipRanks", "published_at": "2026-05-17T05:40:14", "published_display": "17 May 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition", "summary": "Rani Therapeutics reported improved Q1 2026 financial results with increased contract revenue and a narrowed net loss, and expects its cash reserves to fund operations into Q4 2027. However, the company received a Nasdaq warning for failing to meet the minimum bid price requireme", "url": "https://www.stocktitan.net/sec-filings/RANI/8-k-rani-therapeutics-holdings-inc-reports-material-event-dccfb26aea67.html", "source_name": "Stock Titan", "published_at": "2026-05-16T11:42:12", "published_display": "16 May 2026 11:42", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQU2Z5ZGotVVVTbmJwV0t3NXlTZHh5cjNzejJ5U3JUcEtvemZNZE1fX0xTVnJISzREbzZOZ2pPTVdfSWhNWUxzTDc0Y3ROUGJTTW5pcFN6eG0weEF4R0RmRmNLaTY2X2tXaDFOZU1hU21WMmxmN2RuRDFtTEhielB3akdGQXhlMTZweGppSmp0UXRpSExLNl9pb2lHY3FTUXJFV0VNLVVJZlRlRHJP?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/news/rani-therapeutics-participate-h-c-200500021.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:05:00+00:00", "published_display": "12 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rani-therapeutics-holdings-insider-increased-111101166.html", "source_name": "Simply Wall St.", "published_at": "2026-05-08T11:11:01+00:00", "published_display": "08 May 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPXzYxNG5tbVQ3Uno4WkF3aG8xTkxwZzBRUmZwdUl1TU1qYzZ4SkF4NGFUTzVGRTY3Qi1VOEJsaHFDY1N2WWJPNURjWXc1ejZjZkZWVzF4dld0LU1ZVHBtUlFFd216MU0tVndtZE95THVBdmZpamRlb3plNXhpMVVnUTNkcHh6WC1sSUZ5aHJGMlBOaDVJcVZPTC1YUXZWVkZtNDFlSUo3WG1uUnNP?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNbWE3dVAtdE5PU1FXVUk3M3pTY1JySGs5YTdUd1NPSWdjcFFPN21pQkVoYmJ1YXl1aXBaN2oxU1VUWk1RS2Voc01fNUdDUVZ2dVRpalJOblFYbVFxSk5SSlRfZHNKbzc5Mm1UN1pDQ3dmU1FSeERzY0VCalN0RFlrU2lLX2ltWktzRVl0WnhsdDRPVWg3dmVzRHdVdEtEN2o0UVBFcnBaNkhpTl9DU2c?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics (RANI): Valuation in Focus After Landmark Chugai Deal and Breakthrough Clinical Data", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Rani Therapeutics (RANI) Is Up 23.6% After Promising Oral Semaglutide Preclinical Data Release", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending tickers: latest investor updates on Apple, Beyond Meat, Rani Therapeutics, BitMine and B&M", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQy1lalVZc3prZ0l1LWJBTUt5aW9BNW5UOGJ1TmdzcFVkSjFWemRMSG9sNlNpQlktNHBGajJvSXNaZXNqUjlsV0xBZmlWcUxJSVh0R2lpa1pDUnpfTk9CTTNOcE84MWRwdm5GRWl5RkxvbmdBaG8xN1I5bjJDdlZsMl9hUHVQUzdOVlhEOWg0ZG1QeENLZjZCeDE3Z3N3a05LY1E4SGdNWjI3TXdLVGt2cGZR?oc=5", "source_name": "Market source", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Rani Therapeutics\u2019 Stock Skyrocketing Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRGdFdFJDSzRrY1hnN2FqZFFxNHZpYlU0TWpvUmxkSm9MUVM1WndKX2FKVlczakkydGNqYUota09jNEwwb3ZKV1ZkMFZrNmtkZFQ5ZXFQelpGNTFZYWh6Mmpoa2FpV1VWSFZaMEJpYmF1NTR3Q2Q4NW95eUZmdGUzOG1sblB3UFEwc2VObUlKU3lwMjFQOWkyejJ5WU1hV0tCX05TM2Fqck5HVXZMUm9KZFk2aVNsemlWNVFXMWJTcElKZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-17T07:00:00+00:00", "published_display": "17 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Holdings (RANI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9jMWY4aW5GTnlGSHgxWVRYbkhoRk51a2xBd2VvZTIyX2xLM0xUTTVUMzNnLTM4NnR4cVp3MkMtQTNxc0lCUHU1SzJreFpQVTA5QXlB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:24:30+00:00", "published_display": "25 Apr 2025 01:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rani Therapeutics Stock: Excellent Technology But Major Risks Ahead (NASDAQ:RANI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOYXpPV25xa3drX3RILWJab0lGLXRuYVZQdEFCdVFSNmNTM3dWMldiSWdoNFVQYmFSUUdVWFNWVWlpZ2FQWXd3TUV3VFFfT1ZLMllSRXlMOHRjcF9xNFNTVXNrbk9iYzd0bWVMaERaSm1aSmdnREZRNjhRSHFUUXVZT3M5SDRQVDNUR1lYbTd0MlFLZDhiNUpiYTh4V2N1Zw?oc=5", "source_name": "Seeking Alpha", "published_at": "2023-09-19T07:00:00+00:00", "published_display": "19 Sep 2023 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 56, "sentiment_summary": {"positive": 9, "negative": 8, "neutral": 39, "score": 52, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 20.7, "count": 37}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 0.69, "latest_week": "2026-07-10", "one_week_move": -10.9, "four_week_move": -9.6, "twelve_week_move": -28.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.500046, "market_dynamics_buy_signal": false, "relative_strength": -44.030248, "fair_value_gap": -67.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.093, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.9% over one week, -9.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 20}, {"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 6}, {"label": "GlobeNewswire", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "Finimize", "count": 1}, {"label": "Quiver Quantitative", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 37}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.9% over one week, -9.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Rani Therapeutics Tries To Turn Biologic Shots Into Pills"}], "updated_at": "2026-07-16T11:43:13.943132+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}